Snapshot from Jul 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Alamar launches eMTBR-Tau immunoassay
Tech product launch

Alamar launches eMTBR-Tau immunoassay

Analysis based on 6 articles · First reported Jul 07, 2026 · Last updated Jul 07, 2026

Sentiment
40
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The launch positions Alamar Biosciences as a leader in Alzheimer's blood-based diagnostics, potentially expanding its market share in precision proteomics. Positive sentiment is expected due to the unmet need for accessible tau biomarkers, though competition and regulatory risks remain.

biotechnology healthcare diagnostics
Event Summary

Alamar Biosciences, Inc. (Nasdaq: ALMR) launched the first commercial eMTBR-Tau immunoassay on July 7, 2026. The assay measures a plasma biomarker that reflects tau tangle pathology, a core feature of Alzheimer's disease. It is available in the NULISAseq Neuro 220 panel and as a single-plex assay through the Technology Access Program. The launch addresses a critical need for a blood-based biomarker of tau pathology, previously only measurable via expensive tau PET imaging. Alamar will showcase data at AAIC 2026 in London on July 14.

Key Actions
100 Alamar Biosciences launched immunoassay
50 Alamar Biosciences will showcase data
Entities Involved
priv
Alamar Biosciences
Alamar launched the first commercial eMTBR-Tau immunoassay, enhancing its product portfolio and competitive position in Alzheimer's diagnostics.
Importance 100.0 Sentiment 60.0
per
Yuling Luo
As CEO, Yuling Luo announced the launch and highlighted the assay's potential for precision medicine.
Importance 50.0 Sentiment 40.0
ngo
Alzheimer s Association
Alamar will present data at the Alzheimer s Association International Conference (AAIC) 2026, highlighting the assay's relevance to the research community.
Importance 30.0 Sentiment 30.0
priv
Banner Health
Banner Health's Fluid Biomarker Laboratory, led by Nicholas Ashton, endorsed the assay as transformative for Alzheimer's research.
Importance 20.0 Sentiment 30.0
per
Nicholas Ashton
Nicholas Ashton, senior director at Banner Health, provided a supportive quote on the assay's potential.
Importance 20.0 Sentiment 30.0
govactor
United States — United States Securities and Exchange Commission
The SEC is mentioned only in forward-looking statements disclaimers; no direct impact from this event.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.